We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed at $29.39 in the latest trading session, marking a -3.83% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.12%. Meanwhile, the Dow lost 0.13%, and the Nasdaq, a tech-heavy index, added 0.2%.
Coming into today, shares of the company had gained 57.69% in the past month. In that same time, the Medical sector lost 1.25%, while the S&P 500 gained 9.3%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on May 11, 2026. The company's earnings per share (EPS) are projected to be $0.06, reflecting a 70% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $621.4 million, reflecting a 6.04% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.61 per share and revenue of $2.86 billion, indicating changes of +15.09% and +21.97%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 27.25% rise in the Zacks Consensus EPS estimate. As of now, Hims & Hers Health, Inc. holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Hims & Hers Health, Inc. has a Forward P/E ratio of 50.34 right now. Its industry sports an average Forward P/E of 22.37, so one might conclude that Hims & Hers Health, Inc. is trading at a premium comparatively.
We can additionally observe that HIMS currently boasts a PEG ratio of 2.89. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. HIMS's industry had an average PEG ratio of 1.34 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 94, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS - Free Report) closed at $29.39 in the latest trading session, marking a -3.83% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.12%. Meanwhile, the Dow lost 0.13%, and the Nasdaq, a tech-heavy index, added 0.2%.
Coming into today, shares of the company had gained 57.69% in the past month. In that same time, the Medical sector lost 1.25%, while the S&P 500 gained 9.3%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on May 11, 2026. The company's earnings per share (EPS) are projected to be $0.06, reflecting a 70% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $621.4 million, reflecting a 6.04% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.61 per share and revenue of $2.86 billion, indicating changes of +15.09% and +21.97%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 27.25% rise in the Zacks Consensus EPS estimate. As of now, Hims & Hers Health, Inc. holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Hims & Hers Health, Inc. has a Forward P/E ratio of 50.34 right now. Its industry sports an average Forward P/E of 22.37, so one might conclude that Hims & Hers Health, Inc. is trading at a premium comparatively.
We can additionally observe that HIMS currently boasts a PEG ratio of 2.89. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. HIMS's industry had an average PEG ratio of 1.34 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 94, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.